| DC | Dendritic cell |
| DEX | Dendritic cell-derived exosome |
| PLPC | Phospholipoproteic complex |
| TME | Tumor microenvironment |
| MHC | Major histocompatibility complex |
| MHC-I | Major histocompatibility complex class I |
| MHC-II | Major histocompatibility complex class II |
| CD | Cluster of differentiation |
| CD80 | Cluster of differentiation 80 |
| CD86 | Cluster of differentiation 86 |
| HLA-DR | Human leukocyte antigen DR |
| IFN-γ | Interferon gamma |
| IL | Interleukin |
| IL-10 | Interleukin 10 |
| IL-6 | Interleukin 6 |
| NAM | New Approach Methodologies |
| Lo | Liquid-ordered phase |
| Ld | Liquid-disordered phase |
| STIP | Structural Traceability Immunophenotyping Platform |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| CCR7 | C–C chemokine receptor type 7 |
| ROS | Reactive oxygen species |
| TCR | T cell receptor |
| CAR-T | Chimeric antigen receptor T cells |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| iRECIST | Immune Response Evaluation Criteria in Solid Tumors |
| PK | Pharmacokinetics |
| PD | Pharmacodynamics |